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Abstract: Many therapeutic modalities have been used to treat alopecia areata, with variable 
efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, 
many of these therapeutic agents have not been subjected to randomized, controlled trials, and, 
except for topical immunotherapy, there are few published studies on long-term outcomes. The 
treatment plan is designed according to the patient’s age and extent of disease. In this paper, 
the therapeutic agents are organized according to their efficacy and safety profiles into first-line, 
second-line, and third-line options.
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Introduction
Alopecia areata is a common, nonscarring, autoimmune disease that can affect any 
  hair-bearing area. Alopecia areata is a lymphocyte cell-mediated inflammatory type of 
hair loss, but its pathogenesis is not fully understood. The disease can present as a single, 
well demarcated patch of hair loss, multiple patches, or extensive hair loss in a form of 
total loss of scalp hair (alopecia totalis) or loss of entire scalp and body hair (alopecia 
universalis). A number of treatments can induce hair regrowth in alopecia areata but 
do not change the course of the disease. Treatment is more effective in patchy alopecia 
areata than in alopecia totalis/alopecia universalis. Therapy for alopecia areata should be 
tailored in light of severity of the condition and the patient’s age. This review discusses 
the therapeutic options and management strategies for alopecia areata.
First-line therapies
Intralesional corticosteroids
Several studies have shown the efficacy of intralesional corticosteroid injections. 
Abell and Munro reported hair regrowth in 71% of patients with subtotal alopecia 
areata treated by triamcinolone acetonide injections and in 7% of a placebo group.1 
For limited scalp alopecia areata, intralesional corticosteroid therapy is considered 
as the drug of choice by many experts. The most widely used agent is triamcino-
lone acetonide. Different concentrations of triamcinolone acetonide are used, in the 
range of 2.5–10 mg/mL, but 5 mg/mL is the preferred concentration for the scalp 
and face. A maximum volume of 3 mL on the scalp in one visit is recommended. 
Corticosteroid is injected into the deep dermis level or just beneath the dermis in 
the upper   subcutis. The injections can be repeated at 4–6 weekly intervals. The use Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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of mesotherapy multi-injectors with 5–7 needles is an 
alternative approach to decrease injection pain and to make 
the procedure more homogenous.2 Side effects include skin 
atrophy and telangiectasia which can be minimized by the 
use of smaller volumes and avoiding superficial   injections. 
To alleviate injection pain, topical anesthetic may be applied 
30–60 minutes before the treatment. Although the effect of a 
single intralesional corticosteroid injection has been observed 
to persist for up to 9 months,3 reported relapse rates were 
29% in limited alopecia areata and 72% in alopecia totalis 
during a 3-month follow-up period.1
Topical corticosteroids
Many forms of topical corticosteroids have been prescribed 
for alopecia areata, including creams, gels, ointments, 
lotions, and foams. Sixty-one percent of patients using 0.1% 
betamethasone valerate foam achieved more than 75% hair 
regrowth in comparison with 27% in the 0.05% betametha-
sone dipropionate lotion group.4 Topical corticosteroids are 
far less effective in alopecia totalis and alopecia universalis.5 
A highly potent topical corticosteroid under occlusion is 
the preferred method when using topical corticosteroids. 
  Folliculitis is a common side effect to topical corticosteroids. 
Telangiectasia and atrophy may develop rarely. The reported 
relapse rate is 37%–63%.5,6
Minoxidil
In a placebo-controlled, double-blind study, hair regrowth 
was observed in 63.6% and 35.7% of the minoxidil-treated 
and placebo groups, respectively.7 However, only 27% of the 
minoxidil-treated patients showed cosmetically acceptable 
hair regrowth. In another study, hair regrowth was achieved 
in 38% and 81% of patients treated with 1% and 5% 
topical minoxidil, respectively.8 Most studies have shown 
no beneficial effect of topical minoxidil in alopecia totalis 
and alopecia universalis.9 Minoxidil 5% solution or foam is 
frequently used with other therapeutic agents as an adjuvant 
therapy. The adverse effects of topical minoxidil include 
contact dermatitis and facial hypertrichosis.
Anthralin
A few controlled trials have assessed the efficacy of topical 
anthralin in the treatment of alopecia areata. In an open study, 
a cosmetic response was seen in 25% of patients with severe 
alopecia areata treated using 0.5%–1.0% anthralin cream.10 
In another trial, combination therapy of 5% minoxidil and 
0.5% anthralin was used to treat 51 patients with severe 
alopecia areata; only 11% of patients achieved cosmetically 
acceptable hair regrowth.11 Anthralin needs to be applied in 
a high enough concentration (0.5%–1%) and sufficiently 
  frequently (daily) to produce a mild irritant reaction in 
order to be   effective. Severe irritation and staining of skin 
and clothes are some of the possible adverse events with 
anthralin.
Topical immunotherapy
Topical sensitizers that have been used in the treatment of 
alopecia areata include diphenylcyclopropenone, squaric 
acid dibutylester (SADBE), and dinitrochlorobenzene. 
  Dinitrochlorobenzene is no longer used because it was shown 
to be mutagenic in the Ames test.12 Diphenylcyclopropenone 
is the topical sensitizer of choice. SADBE is expensive and 
not stable in acetone.13 Diphenylcyclopropenone is light-
sensitive and should be protected from light.14
Initially the patient is sensitized using a 2% solution of 
diphenylcyclopropenone applied to a 4 × 4 cm area of the 
scalp. After two weeks, 0.001% diphenylcyclopropenone 
solution is applied to the same half of the scalp. The diphe-
nylcyclopropenone concentration is increased gradually 
every week until mild dermatitis is observed.15 The solution 
should be on the scalp for 48 hours. The scalp should be 
protected from the sun during this time. Once hair regrowth 
is obtained on the treated half of the scalp, both sides are 
treated. Both sides of the scalp can be treated from the start 
also. Diphenylcyclopropenone is applied on a weekly basis 
by a trained nurse. If there is no response after 6 months of 
treatment, diphenylcyclopropenone can be discontinued. 
SADBE may be tried in poor responders to diphenylcyclopro-
penone or in those who do not develop a sensitization to 2% 
diphenylcyclopropenone. SADBE is applied once or twice 
per week.16,17 The adverse effects to topical sensitizers include 
cervical lymphadenopathy, a severe eczematous reaction, 
urticaria, and postinflammatory pigment changes.18,19
The response rate of alopecia totalis/alopecia universalis 
patients to diphenylcyclopropenone was 17.4% in the largest 
reported diphenylcyclopropenone study, whereas the cumula-
tive patient response was 77%.20 Several negative prognostic 
factors in the treatment of alopecia areata with diphenylcy-
clopropenone have been suggested, including long duration 
of disease, alopecia totalis/alopecia universalis, nail changes, 
atopy, and family history of alopecia areata.20–22 Recurrence 
of alopecia areata after achieving significant hair regrowth 
developed in 62.6% of patients.20 In a retrospective study of 
121 patients with extensive alopecia areata, fexofenadine 
hydrochloride has been shown to enhance the efficacy of 
topical immunotherapy.23Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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The mechanism of action of topical sensitizers could be 
due to perifollicular lymphocyte apoptosis,24 changes in the 
peribulbar CD4/CD8 lymphocyte ratio,25,26 and antigenic 
competition.27
Prostaglandin analogs
Eyelash hypertrichosis is a common adverse effect to the use 
of these antiglaucoma eye drops.28–30 Some case series did 
not show an effect in the treatment of eyelashes in patients 
with alopecia areata.31,32 In a nonrandomized, controlled 
study of latanoprost (a prostaglandin F2α analog) eye drops 
in patients with alopecia universalis, acceptable results 
(total and moderate hair regrowth) were achieved in 45% of 
patients.33 In another retrospective trial, 0.03% bimatoprost 
eye drops were used once a day for one year. Complete 
regrowth of the eyelashes was noted in 24.3% of patients 
and moderate growth in 18.9% of treated subjects.34 Relapses 
were observed in 17.5% of the patients, mainly in the slight 
response group.33
Topical retinoids
In a comparative study of topical tretinoin 0.05%,   topical 
betamethasone dipropionate lotion, and dithranol paste 
0.25%, a good response has been seen in 55% of patients 
treated with topical tretinoin in comparison with 70% 
and 35% in the topical steroid and dithranol groups, 
  respectively.35 Although the mechanism for its action in 
alopecia areata is not completely understood, the associated 
tretinoin-induced dermatitis might contribute to regrowth 
in alopecia areata. Larger, double-blind, placebo-controlled 
trials are needed.
Bexarotene
In a randomized bilateral half-head study, hair regrowth of 
at least 50% on treated sites was noticed in only 26% of 
patients treated with 1% bexarotene gel.36 Mild irritation is 
a common side effect.
Capsaicin
In a nonblinded randomized study, 9.5% of patients with 
alopecia areata showed cosmetically acceptable hair regrowth 
after 12 weeks of applying capsaicin ointment.37
Second-line therapies
Sulfasalazine 
Sulfasalazine is a combination of sulfapyridine and 
5-  aminosalicylic acid linked by a diazo bond. Sulfasalazine 
has both immunomodulatory and immunosuppressive actions 
that include suppression of T cell proliferation and reducing 
the synthesis of cytokines, including interleukin (IL) 6, 1, 
and 12, tumor necrosis factor alpha, and antibody production.38 
Sulfasalazine has been used safely as a long-term treatment 
of various inflammatory and autoimmune diseases, including 
inflammatory bowel disease and rheumatoid arthritis. Several 
case reports and case series showed good hair regrowth with 
sulfasalazine in the treatment of alopecia areata.
In an uncontrolled prospective trial of sulfasalazine in 
39 patients with persistent alopecia areata, hair regrowth 
of more than 60% was achieved in 25.6% of patients. 
A moderate response was seen in 30.7% of patients.39 Also, 
in another uncontrolled open-label study, complete hair 
regrowth was reported in 27.3% of subjects.40 Sulfasalazine 
was started at 500 mg twice daily for one month, 1 g twice 
daily for one month, and then 1 g three times daily.41 Side 
effects to sulfasalazine include gastrointestinal distress, 
dizziness, and headache.39 Gastrointestinal symptoms can 
be minimized by using enteric-coated tablets, taking the 
medication with food, and starting at lower doses. Initially, 
patients should have a complete blood count, liver function 
tests, creatinine, and glucose-6-phosphate dehydrogenase 
level measurement. Complete blood counts and liver func-
tion tests should be performed at 2–4-week intervals during 
the first three months of therapy. The reported relapse rates 
are 22.7%–45.5%.39,40
Photochemotherapy
The success rate for oral and topical psoralen plus ultraviolet 
A (PUVA) ranged from 15% to more than 70%.42,43 PUVA-
turban is a method of administering a dilute psoralen solution 
(8-methoxypsoralen 0.0001%) selectively to the scalp for 
20 minutes using a cotton towel as a turban. The patient’s scalp 
is then exposed to ultraviolet A radiation.44 Treatment sessions 
are performed two or three times per week.   PUVA-turban has 
been shown to be effective in about 70% of treated patients.44,45 
During a follow-up period of 15 months after PUVA-turban 
therapy, recurrences of alopecia areata were observed in 26% 
of responders.44 PUVA-turban therapy lacks the systemic side 
effects of oral PUVA and can be considered as alternative 
therapy for patients with alopecia areata.
excimer laser
In a treatment of 42 alopecia areata patches with the 308 nm 
excimer laser, hair regrowth was observed in 41.5% of treated 
areas.46 Hair regrowth was noticed to begin to appear during 
the second month of therapy. No regrowth of hair was noted 
on the control patches. Laser therapy was administered twice Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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a week for a maximum of 24 sessions. Apart from erythema 
at the treated sites, there were no significant adverse effects. 
Relapses of alopecia areata were observed in two patients 
with patchy alopecia areata of the scalp who had shown 
complete regrowth earlier. Also, the use of excimer laser in 
children with alopecia areata has been reported to have a 
good success rate.47
Fractional photothermolysis laser
Good hair regrowth was achieved with fractional Er: Glass 
laser in a single case report.48 Randomized controlled trials 
in a larger number of patients are required to confirm the 
efficacy of this modality of treatment.
Third-line therapies
Systemic corticosteroids
Systemic corticosteroids are one of the commonly 
  prescribed therapies in patients with extensive alopecia 
areata.   Various forms of corticosteroids have been used in 
  different   regimens. In one study, a once-monthly oral pulse 
of 300 mg prednisone induced a complete response in 41% 
of patients.49 A similar effect has been reported in a placebo-
controlled trial of oral prednisolone 200 mg once weekly 
in the   treatment of extensive alopecia areata.50 The relapse 
rate was 25%, and side effects of the therapy were noted in 
55% of patients.50 In a comparative trial, the response rate 
was better in patients treated with intramuscular triamcino-
lone acetonide 40 mg once monthly than in those treated 
with oral dexamethasone 0.5 mg/day.51 In the same study, 
impairment of adrenocortical reserve was seen in 23% of 
the intramuscular triamcinolone acetonide group and in 
7% of patients treated with oral prednisolone pulse therapy 
of 80 mg for 3 consecutive days once every 3 months. In 
a study of 139 patients treated with pulse corticosteroid 
therapy, a good response was achieved in 59.4% of patients 
with   recent-onset disease (duration of alopecia areata up to 
6 months) in comparison with 15.8% of subjects who had 
had alopecia areata for more than 6 months.52 Alopecia totalis 
and alopecia universalis are far less responsive to this therapy 
than patchy alopecia areata.53 The use of systemic corticos-
teroids is limited by their side effects (hyperglycemia, weight 
gain, hypertension, adrenal suppression, dysmenorrhea, 
immunosuppression, and acneiform eruption)50,54 and the 
high relapse rate (14%–100%).51,55,56
Methotrexate
In a long-term follow-up study of methotrexate in 33 patients 
with alopecia areata, complete hair regrowth was achieved 
in 57% and 63% of patients who used methotrexate alone 
or with low doses of oral corticosteroids (prednisone 
10–20 mg/day), respectively.57 Thirty percent of patients had 
partial hair regrowth. The weekly dosages of methotrexate 
were 15–25 mg. The onset of hair regrowth was seen after a 
median delay of three months. Recurrences of alopecia areata 
after a decrease of the methotrexate dose or after stopping 
treatment were observed in 57% (8/14 cases) of responders. 
In a retrospective trial of methotrexate in 14 children with 
alopecia areata, approximately one third of patients experi-
enced a clinically relevant therapeutic response.58 The mean 
age of the patients was 14.7 (range 8–18) years. Adverse 
effects to methotrexate include persistent nausea, transient 
elevation of hepatic enzymes, and leucopenia.
Cyclosporine
The success rate with oral cyclosporine is 25%–76.6%.59,60 
A recent study showed that a good response to oral 
cyclosporine can be predicted if the serum level of IL 18 is 
elevated and the level of soluble IL 2 receptor is low.61 The 
use of oral cyclosporine in patients with alopecia areata is 
not generally favored due to its adverse event profile (neph-
rotoxicity, immune suppression, and hypertension) and a high 
relapse rate (up to 100%).62 Also, alopecia areata incidence has 
been reported in several organ transplant patients receiving 
cyclosporine.63–66 Although hypertrichosis is a documented 
side effect of oral cyclosporine,67 a good response has not been 
achieved by using topical cyclosporine in humans.68,69
Azathioprine
Azathioprine, a thiopurine analog immunosuppressive drug, 
has been used to treat a vast array of autoimmune diseases. 
It inhibits DNA synthesis and thus decreases proliferation 
of cells, especially T and B lymphocytes. Azathioprine 
also decreases the number of Langerhans cells and other 
antigen-presenting cells in the skin. In a recent pilot study 
of 20 patients treated with azathioprine 2 mg/kg/day as 
monotherapy, mean hair regrowth was 52.3% ± 38.4%.70 
These results need to be confirmed in large-scale, random-
ized, controlled studies.
Biologics
Although tumor necrosis factor alpha is implicated in the 
pathogenesis of alopecia areata, there are several reported 
cases that have shown either development of alopecia 
areata or complete failure to respond to different tumor 
necrosis factor alpha inhibitors, including adalimumab,71,74 
infliximab,75,76 and etanercept.77–79 In a prospective trial of Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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17 patients with alopecia areata, Strober et al concluded 
that etanercept does not effectively treat moderate to severe 
alopecia areata.80 Also, in a placebo-controlled study, Price 
et al showed that efalizumab, an anti-CD11a antibody, is not 
effective in the treatment of alopecia areata.81 Some clinical 
trials are ongoing to evaluate the efficacy of the newer bio-
logic therapies in the treatment of alopecia areata.
Psychological support
Alopecia areata is considered to be an example of a 
  psychosomatic disorder, leading to dramatic and devastating 
emotions which can negatively impact patient self-esteem, 
body image, and self-confidence.82
One important step that should not be overlooked during 
the course of management of alopecia areata is offering 
psychological support to foster increased self-esteem and 
adaptation to this disease. Helping patients with alopecia 
areata cope with depression and an unpredictable disease 
like alopecia areata can be achieved by several ways, 
including education of the patient about the nature of dis-
ease, psychotherapy, hypnotherapy,83 antidepressants,84,85 
and support groups. Hypnotherapy may significantly 
improve depression, anxiety, and quality of life, but not 
hair regrowth.86 Patients with extensive disease may wear 
scalp prostheses, such as wigs, hairpieces, or other scalp 
coverings.
Other therapies
Other therapeutic agents have been tried, with some degree 
of success. These modalities include aromatherapy,87 
a   combination of topical garlic gel and betamethasone valerate 
cream,88 topical azelic acid,89 oral zinc supplementation,90–92 
topical onion juice,93 a simvastatin-ezetimibe combination,94,95 
inosiplex,96–98 and intralesional injections of candida antigen.99 
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These treatment modalities need to be confirmed in large-
scale, double-blind, placebo-controlled trials.
There are other modalities of therapy that have not shown 
good efficacy. These agents include imiquimod,100,101 topical 
calcineurin inhibitors,102–106 botulinum toxin type A,107 topical 
tri-iodothyronine ointment,108 photodynamic therapy,109–111 
and topical 5-fluorounacil.112
Management plan
Treatment options should be selected according to patient 
age and extent of disease. For patients younger than 10 years, 
a combination of 5% minoxidil solution twice daily with 
midpotent corticosteroids should be tried first. If there is no 
good improvement after 6 months, short-contact anthralin 
is considered as second-line therapy. Excimer laser can be 
used, particularly in patchy alopecia areata.
For patients older than 10 years of age with alopecia areata 
involving less than 50% of the scalp, intralesional triamcino-
lone acetonide injection (5 mg/cc) is the recommended option 
for treatment. If there is no good response after 6 months, other 
options can be tried, including potent topical corticosteroids 
under occlusion at night, 5% topical minoxidil twice a day, 
short-contact anthralin, and excimer laser.
If alopecia areata involves more than 50% of the scalp, 
topical immunotherapy with diphenylcyclopropenone is the 
first therapeutic option recommended by many experts in hair 
diseases. Intralesional injections of triamcinolone acetonide 
are used to treat persistent alopecic patches.
For patients who respond poorly to diphenylcycloprope-
none and those who cannot use it, second-line therapies can be 
used. Several reviews of alopecia areata therapy suggest topi-
cal minoxidil and topical corticosteroids113–116 but, as discussed 
earlier, the yield of these topical agents in the treatment of 
extensive alopecia areata is limited. Therefore, we suggest that 
patients with extensive resistant disease can use sulfasalazine 
with or without systemic   corticosteroids. Systemic steroids 
are used as bridge therapy until the sulfasalazine takes effect. 
Treatment with sulfasalazine is generally well tolerated and 
characterized by a lower incidence of serious side effects in 
comparison with other systemic therapies like corticosteroids 
and methotrexate. The other second-line therapy is PUVA-
turban. It is a well tolerated therapy with minimal local pho-
totoxic side effects and without the systemic side effects of 
PUVA. These options are selected based on a balance between 
the efficacy and safety of these therapeutic agents.
If these therapies fail or are not tolerated, third-line 
therapeutic options can be discussed with patients in terms 
of the expected outcome of therapy and possible side effects. 
These agents include methotrexate with or without a systemic 
corticosteroid, azathioprine, cyclosporine, and pulse therapy 
of corticosteroids. While using these drugs, close   monitoring 
of patients is important to avoid possible side effects. 
A summary of an alopecia areata treatment plan is shown as 
an algorithmic approach in Figure 1.
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